Exeliom Biosciences
- Biotech or pharma, therapeutic R&D
Exeliom Biosciences is a clinical-stage immunotherapy company developing EXL01, a NOD2-targeting, single-strain live biotherapeutic designed to enhance the efficacy of checkpoint inhibitors by reprogramming macrophages.
EXL01 is currently being evaluated in six Phase II trials, including four active oncology studies in gastric cancer, NSCLC, HCC, and RCC in combination with PD-1 or PD-L1 inhibitors. Key clinical readouts are expected over the next 18 to 24 months, including an interim analysis in 1L gastric cancer (n=120) in mid-2026. To date, EXL01 has shown promising target engagement results in patients.
Derived from Faecalibacterium prausnitzii, EXL01 selectively activates the NOD2 pathway, driving context-specific macrophage polarization.
Beyond oncology, EXL01 is being clinically evaluated in two Phase 2 placebo-controlled trials in IBD and recurrent C. difficile, offering additional upside in immuno-inflammatory and infectious diseases.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}